Medical cannabis and cannabinoid-based therapies are gaining
wider acceptance around the United States. More than 20 states and the District
of Columbia have legalized the drug and, between 2009 and 2014, IBISWorld
estimates that the medical cannabis industry grew significantly to reach $2
billion in revenue. Despite this industry boom and the pioneers that emerged
within it, there has been a shortage of companies conducting legitimate
research and development and/or with the right amount of scientific backing and
funding needed to compete in the industry.
GrowBLOX Sciences, a biopharmaceutical research and
development company, stands out from the pack with its advanced technologies in
plant biology and cultivation. Led by an impressive scientific team that
includes big data experts, the company has turned its attention to creating
safe, standardized pharmaceutical-grade cannabis-based therapies that target an
assortment of medical conditions. The company is focused on bringing relief to
patients in communities across the country by combining ground-breaking
technology and industry processes with its “big” data-driven clinical research
and development loop ability. Moreover, through its Puerto Rico subsidiary,
GrowBLOX Sciences is developing and dispensing its suite of cultivation and
growing chambers worldwide.
With its novel approach to using big data to produce
lower-risk clinical trial candidates, GrowBLOX is highlighting its strong
long-term potential. With over 180 cannabis-related human trials registered
with the National Institute of Health (NIH) and more on the way, the company
has established a brilliant starting point with close to a thousand potential
combinations within the cannabinoid-related therapy space.
In the short term, the company intends to earn revenue from
selling certified raw materials through dispensaries. These near-term plans
were set in May when the company announced the formation of GrowBLOX Sciences
Puerto Rico, a subsidiary that will legally grow cannabis raw materials that will
be sold solely to its parent company for dispersion in the U.S. and other
countries where the drug is legal.
The company’s operations – cultivation, post-processing and
manufacturing – create a model platform to execute these visions. On the
cultivation side, its TissueBLOX, GrowBLOX and CureBLOX platforms facilitate
the efficient growing of cannabis, while its ExtractionLab produces proprietary
blends for distribution as pharmaceuticals, nutraceuticals and cosmeceuticals.
Given its distinctive business model, long-term potential in pharmaceuticals
and short-term potential in raw material sales, GrowBLOX Sciences is a company
worth a closer look.
For more information, visit the company’s website at
www.growblox.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment